Bronchiolitis: what the clinician should know
Bronchiolitis is an acute infection of the lower respiratory tract affecting infants and young children, with Respiratory Syncytial Virus (RSV) being the most common pathogen. Bronchiolitis is generally a mild disease, but may present with severe signs and symptoms requiring hospitalization. Risk fa...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hygeia Press di Corridori Marinella
2015-10-01
|
Series: | Journal of Pediatric and Neonatal Individualized Medicine |
Subjects: | |
Online Access: | https://www.jpnim.com/index.php/jpnim/article/view/309 |
id |
doaj-2015a727486644b8a23934c1d96f8d66 |
---|---|
record_format |
Article |
spelling |
doaj-2015a727486644b8a23934c1d96f8d662020-11-25T02:44:04ZengHygeia Press di Corridori MarinellaJournal of Pediatric and Neonatal Individualized Medicine2281-06922015-10-0142e040217e04021710.7363/040217251Bronchiolitis: what the clinician should knowRoberto Antonucci0Anna Maria Oggiano1Pediatric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, ItalyPediatric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, ItalyBronchiolitis is an acute infection of the lower respiratory tract affecting infants and young children, with Respiratory Syncytial Virus (RSV) being the most common pathogen. Bronchiolitis is generally a mild disease, but may present with severe signs and symptoms requiring hospitalization. Risk factors including prematurity, bronchopulmonary dysplasia, immunodeficiency and congenital heart defects may predispose patients to develop a severe disease. The diagnosis should be based on clinical evaluation, without supportive radiographic and laboratory studies. Etiological diagnosis may be helpful to decrease the hospital transmission of virus and to avoid inappropriate use of antibiotics. The mainstay of therapy for bronchiolitis is supportive care, which should be directed at maintaining adequate oxygenation, ensuring a proper respiratory toilet, and meeting the requirements of fluids and nutrition. The use of nebulized hypertonic saline should be limited to hospitalized patients. Severe respiratory failure may require mechanical ventilatory support. Neither corticosteroids nor antibiotics offer consistent benefit in the treatment of bronchiolitis, and thus should not be used. A trial of a bronchodilator may be appropriate, but should be continued exclusively if a prompt favorable response occurs. Effective interventions to prevent the spread of RSV infection include hand washing or disinfection by caregivers and contact isolation. The use of palivizumab, a monoclonal antibody directed against RSV, is a safe prophylactic option, but should be restricted to children at high-risk for severe RSV disease, during the epidemic period. Current evidence suggests that early RSV bronchiolitis predisposes children to recurrent wheezing and asthma in the first decade of life. Proceedings of the 11th International Workshop on Neonatology and Satellite Meetings · Cagliari (Italy) · October 26th-31st, 2015 · From the womb to the adult Guest Editors: Vassilios Fanos (Cagliari, Italy), Michele Mussap (Genoa, Italy), Antonio Del Vecchio (Bari, Italy), Bo Sun (Shanghai, China), Dorret I. Boomsma (Amsterdam, the Netherlands), Gavino Faa (Cagliari, Italy), Antonio Giordano (Philadelphia, USA)https://www.jpnim.com/index.php/jpnim/article/view/309bronchiolitisrespiratory syncytial virustherapycomplicationsinfantschildren |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roberto Antonucci Anna Maria Oggiano |
spellingShingle |
Roberto Antonucci Anna Maria Oggiano Bronchiolitis: what the clinician should know Journal of Pediatric and Neonatal Individualized Medicine bronchiolitis respiratory syncytial virus therapy complications infants children |
author_facet |
Roberto Antonucci Anna Maria Oggiano |
author_sort |
Roberto Antonucci |
title |
Bronchiolitis: what the clinician should know |
title_short |
Bronchiolitis: what the clinician should know |
title_full |
Bronchiolitis: what the clinician should know |
title_fullStr |
Bronchiolitis: what the clinician should know |
title_full_unstemmed |
Bronchiolitis: what the clinician should know |
title_sort |
bronchiolitis: what the clinician should know |
publisher |
Hygeia Press di Corridori Marinella |
series |
Journal of Pediatric and Neonatal Individualized Medicine |
issn |
2281-0692 |
publishDate |
2015-10-01 |
description |
Bronchiolitis is an acute infection of the lower respiratory tract affecting infants and young children, with Respiratory Syncytial Virus (RSV) being the most common pathogen. Bronchiolitis is generally a mild disease, but may present with severe signs and symptoms requiring hospitalization. Risk factors including prematurity, bronchopulmonary dysplasia, immunodeficiency and congenital heart defects may predispose patients to develop a severe disease. The diagnosis should be based on clinical evaluation, without supportive radiographic and laboratory studies. Etiological diagnosis may be helpful to decrease the hospital transmission of virus and to avoid inappropriate use of antibiotics.
The mainstay of therapy for bronchiolitis is supportive care, which should be directed at maintaining adequate oxygenation, ensuring a proper respiratory toilet, and meeting the requirements of fluids and nutrition. The use of nebulized hypertonic saline should be limited to hospitalized patients. Severe respiratory failure may require mechanical ventilatory support. Neither corticosteroids nor antibiotics offer consistent benefit in the treatment of bronchiolitis, and thus should not be used. A trial of a bronchodilator may be appropriate, but should be continued exclusively if a prompt favorable response occurs. Effective interventions to prevent the spread of RSV infection include hand washing or disinfection by caregivers and contact isolation. The use of palivizumab, a monoclonal antibody directed against RSV, is a safe prophylactic option, but should be restricted to children at high-risk for severe RSV disease, during the epidemic period. Current evidence suggests that early RSV bronchiolitis predisposes children to recurrent wheezing and asthma in the first decade of life.
Proceedings of the 11th International Workshop on Neonatology and Satellite Meetings · Cagliari (Italy) · October 26th-31st, 2015 · From the womb to the adult
Guest Editors: Vassilios Fanos (Cagliari, Italy), Michele Mussap (Genoa, Italy), Antonio Del Vecchio (Bari, Italy), Bo Sun (Shanghai, China), Dorret I. Boomsma (Amsterdam, the Netherlands), Gavino Faa (Cagliari, Italy), Antonio Giordano (Philadelphia, USA) |
topic |
bronchiolitis respiratory syncytial virus therapy complications infants children |
url |
https://www.jpnim.com/index.php/jpnim/article/view/309 |
work_keys_str_mv |
AT robertoantonucci bronchiolitiswhattheclinicianshouldknow AT annamariaoggiano bronchiolitiswhattheclinicianshouldknow |
_version_ |
1724767703679369216 |